Document -
Athera completes financing to advance clinic with immunovascular antibody
Athera Biotechnologies AB has completed a 57 million SEK financing from current major owners, together with new investor Ribbskottet AB. The investment will be used to fully finance the next steps in clinical development of Athera’s lead project PC-mAb, currently preparing for start of clinical Phase 2.
go to media item
- License:
- Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: